Genocea Biosciences

Genocea Biosciences is a biopharmaceutical company that was founded in 2006. The company focuses on developing innovative vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate, GEN-003, is an immunotherapy designed for the treatment of genital herpes, and it also has a pre-clinical immuno-oncology program aimed at personalized cancer vaccines. Genocea specializes in developing vaccines and immunotherapies using its AnTigen Lead Acquisition System, which is designed for this purpose. The company operates within the biotechnology and health care industries through a single segment dedicated to developing and commercializing vaccines. The most recent investment in Genocea Biosciences was a $80.00M Post-IPO Equity investment on 22 July 2020. As of now, the company has not disclosed the specific investors involved in this latest funding round. Genocea's focus on addressing critical unmet medical needs through cutting-edge antigen identification methodologies positions it as a promising player in the biopharmaceutical industry. This distinctive approach, along with its promising product pipeline, makes Genocea Biosciences an attractive prospect for venture capital firms seeking investment opportunities in the healthcare sector.